Plant Name: Melochia tomentosa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; ADRA2C; ADRA2A; | |
| NMUR2; | |
| ALPL; RECQL; FAAH; TDP1; P4HB; TERT; PKM; HPGD; PGD; AKR1B1; HSD17B10; ALOX15; ALDH1A1; POLB; | |
| GAA; ACHE; | |
| BCL2; | |
| KCNH2; | |
| MET; MAPK1; MAPK14; DYRK1A; | |
| PPARA; PPARD; PPARG; | |
| NR1I2; | |
| KDM4E; | |
| PTGS1; | |
| BACE1; | |
| MMP2; MMP14; | |
| NFKB1; | |
| DNMT1; | |
| ABCB1; | |
| SLCO1B3; SLCO1B1; | |
| LMNA; FABP3; MAPT; FABP5; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP14 | Matrix metalloproteinase 14 | P50281 | CHEMBL3869 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Potassium channels | KCNH2 | HERG | Q12809 | CHEMBL240 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.189E-08 | 1.618E-05 | AKR1B1, ALDH1A1, ALOX15, GAA, HPGD, HSD17B10, KDM4E, MAPK14, P4HB, PGD, PKM, PPARD, PPARG, PTGS1 |
| BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 1.761E-08 | 2.255E-05 | ABCB1, ADRA2A, APP, DYRK1A, FFAR4, LMNA, MAPK1, MAPK14, MAPT, MET, MMP2, NFKB1, P4HB, PPARA, PPARD, PPARG, TERT |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 2.570E-07 | 1.696E-04 | ACHE, ADRA2A, ADRA2C, AKR1B1, ALDH1A1, FFAR1, FFAR4, NFKB1, PPARD, SLCO1B1 |
| BP | GO:0051179; localization | GO:0051050; positive regulation of transport | 1.837E-06 | 8.332E-04 | ABCB1, ACHE, ADRA2A, APP, BCL2, FFAR1, KCNH2, MAPK1, MAPK14, PPARD, PPARG, TERT |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 4.724E-06 | 1.607E-03 | BCL2, LMNA, P4HB, PPARD, TERT |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 5.514E-06 | 1.819E-03 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 7.408E-06 | 2.124E-03 | ALOX15, ALPL, BCL2, MMP14, MMP2 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 7.731E-06 | 2.186E-03 | FFAR4, NFKB1, PPARA, PPARD, PPARG |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 8.587E-06 | 2.397E-03 | ADRA2A, APP, BCL2, MAPK1, MAPK14, MET, MMP14, TERT |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 8.767E-06 | 2.417E-03 | BCL2, MAPK14, MAPT, MET, PPARG |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 1.020E-05 | 2.708E-03 | ADRA2A, AKR1B1, APP, BCL2, FABP3, FFAR1, KCNH2, MAPK1, MET, NMUR2, PPARG |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.164E-05 | 2.982E-03 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0006979; response to oxidative stress | 1.545E-05 | 3.658E-03 | AKR1B1, APP, BCL2, MAPK1, MMP14, P4HB, PTGS1 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.662E-05 | 3.891E-03 | ADRA2A, ADRA2C |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.886E-05 | 4.159E-03 | HPGD, MMP2, TERT |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 3.319E-05 | 6.570E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 3.319E-05 | 6.570E-03 | ADRA2A, ADRA2C |
| BP | GO:0032501; multicellular organismal process | GO:0051239; regulation of multicellular organismal process | 4.964E-05 | 8.717E-03 | ADRA2A, ADRA2C, APP, BCL2, FFAR4, GAA, KCNH2, LMNA, MAPK1, MAPK14, MAPT, MET, MMP14, NFKB1, NMUR2, PPARD, PPARG, TERT |
| BP | GO:0032502; developmental process | GO:0009888; tissue development | 5.055E-05 | 8.806E-03 | ALOX15, ALPL, FABP5, GAA, MAPK14, PKM, PPARA, PPARD |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 5.523E-05 | 9.180E-03 | PPARA, PPARG |
| MF | GO:0005488; binding | GO:0051525; NFAT protein binding | 5.523E-05 | 9.180E-03 | MAPK14, PPARA |
| BP | GO:0065007; biological regulation | GO:0010952; positive regulation of peptidase activity | 5.692E-05 | 9.390E-03 | APP, MAPK14, MAPT, MMP14, PPARG |
| BP | GO:0009987; cellular process | GO:0050708; regulation of protein secretion | 5.972E-05 | 9.633E-03 | ACHE, ADRA2A, ADRA2C, FFAR1, FFAR4, MAPK14, PPARD |
| MF | GO:0003824; catalytic activity | GO:0051213; dioxygenase activity | 6.192E-05 | 9.914E-03 | ALOX15, KDM4E, P4HB, PTGS1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.457E-06 | 2.575E-04 | MMP2; BCL2; MAPK1; MAPK14; NFKB1 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 5.181E-07 | 7.719E-05 | FABP3; FABP5; PPARG; PPARA; PPARD |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.162E-05 | 1.439E-03 | MMP2; BCL2; MAPK1; PPARG; MET; NFKB1; PPARD |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 5.654E-05 | 1.439E-03 | MMP14; MMP2; MAPK1; MAPK14 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 4.088E-05 | 1.439E-03 | BACE1; APP; MAPK1; MAPT; HSD17B10 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.796E-05 | 1.439E-03 | DNMT1; ABCB1; BCL2; MAPK1; MET; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.183E-04 | 2.242E-03 | MMP14; MAPK1; MAPK14; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.269E-04 | 2.242E-03 | APP; ALOX15; MAPK1; PTGS1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.552E-04 | 2.242E-03 | BCL2; MAPK1; MAPK14; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.655E-04 | 2.242E-03 | BCL2; MAPK1; MAPK14; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.655E-04 | 2.242E-03 | BCL2; MAPK1; MAPK14; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.987E-04 | 2.844E-03 | LMNA; BCL2; MAPK1; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.386E-04 | 2.815E-03 | MAPK1; PPARG; MAPK14; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.456E-04 | 2.815E-03 | MAPK1; MAPK14; PPARA; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.214E-04 | 3.694E-03 | DNMT1; PKM; GAA; ALOX15; ALDH1A1; AKR1B1; ALPL; PGD; HSD17B10; PTGS1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.054E-04 | 2.844E-03 | MAPK1; NFKB1; PPARD |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.054E-04 | 2.844E-03 | MAPK1; MAPK14; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.921E-04 | 3.829E-03 | PKM; MAPK1; MET |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 5.139E-04 | 3.829E-03 | MAPK14; MET; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 6.077E-04 | 4.099E-03 | MAPK1; MAPK14; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 7.394E-04 | 4.407E-03 | BCL2; MAPK1; MAPK14; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 4.501E-04 | 3.726E-03 | MAPK1; MAPK14; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.205E-03 | 6.189E-03 | MMP2; MAPK1; MAPK14; MET |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 6.327E-04 | 4.099E-03 | MAPK1; MAPK14; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 7.709E-04 | 4.418E-03 | HPGD; PPARG; MET; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.249E-03 | 6.203E-03 | POLB; PKM; MAPK1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.833E-04 | 4.099E-03 | SLCO1B1; ABCB1; SLCO1B3 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.126E-03 | 5.992E-03 | BCL2; MAPK1; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 6.847E-04 | 4.251E-03 | MAPK1; MAPK14; NFKB1 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 1.621E-03 | 7.725E-03 | FAAH; MAPK1; MAPK14 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.020E-03 | 5.627E-03 | MAPK1; MAPK14; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.715E-03 | 7.725E-03 | BCL2; MAPK1; NFKB1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.123E-03 | 8.472E-03 | ACHE; BCL2; MAPK1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.763E-03 | 7.725E-03 | MAPK1; MAPK14; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.861E-03 | 7.924E-03 | MAPK1; MAPK14; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.767E-03 | 1.034E-02 | MAPK1; MAPT; MAPK14; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.763E-03 | 7.725E-03 | MAPK1; MAPK14; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.777E-03 | 1.034E-02 | MAPK1; MAPK14; PTGS1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.598E-03 | 1.631E-02 | BCL2; MAPK1; NFKB1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 4.776E-03 | 1.655E-02 | BCL2; MAPK1; MAPK14 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 7.714E-03 | 2.394E-02 | BCL2; MAPK1; MET; NFKB1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 6.672E-03 | 2.161E-02 | MAPK1; ADRA2C; ADRA2A |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 7.587E-03 | 2.394E-02 | MAPK1; MAPK14; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.120E-02 | 2.858E-02 | BCL2; MAPK14; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.076E-02 | 2.858E-02 | MAPK1; PPARA; NFKB1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.120E-02 | 2.858E-02 | BCL2; MAPK1; MET |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.259E-02 | 2.932E-02 | MAPK1; MAPK14; MET |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.530E-02 | 3.508E-02 | MAPK1; MET; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.143E-02 | 4.561E-02 | POLB; TERT; NFKB1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 8.688E-03 | 2.619E-02 | MAPK1; MAPK14 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.071E-02 | 2.858E-02 | MAPK1; MAPK14 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.011E-02 | 2.842E-02 | MAPK1; MET |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.011E-02 | 2.842E-02 | MAPK1; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 8.965E-03 | 2.619E-02 | BCL2; MAPK1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.139E-02 | 4.561E-02 | MAPK1; MAPK14 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.978E-02 | 4.334E-02 | PPARG; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.226E-02 | 2.932E-02 | MAPK1; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.180E-02 | 4.574E-02 | MMP2; MAPK1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.163E-02 | 2.888E-02 | MAPK1; MET |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.226E-02 | 2.932E-02 | MAPK1; NFKB1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 2.262E-02 | 4.682E-02 | PKM; PPARA |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.965E-03 | 2.619E-02 | ALOX15; PTGS1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.939E-02 | 4.312E-02 | BCL2; NFKB1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 5.458E-03 | 1.848E-02 | PKM; MAPK1 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 6.142E-03 | 2.034E-02 | BCL2; MAPK14 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.673E-02 | 3.778E-02 | BCL2; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.132E-02 | 2.858E-02 | PPARA; NFKB1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.008E-03 | 1.457E-02 | MMP2; MAPK1 |
| hsa04622 | RIG-I-like receptor signaling pathway_Homo sapiens_hsa04622 | 1.132E-02 | 2.858E-02 | MAPK14; NFKB1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.258E-02 | 2.932E-02 | MAPK1; MET |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.020E-03 | 8.359E-03 | MAPK1; PPARG |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.161E-03 | 8.472E-03 | GAA; AKR1B1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; PPARG |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| C00-D49: Neoplasms | Cancer | C00-C96 | BCL2; BCL2; ABCB1; MET; MAPK1; MAPK14; NFKB1; MMP2; ACHE; DNMT1; APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C |
| C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1; TERT; MMP2 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MAPK14; AKR1B1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1; MET; MAPK1; MMP2; MMP14; PKM |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; NFKB1; PPARD; PPARG; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | BCL2; MAPK14 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
| C00-D49: Neoplasms | Prostate cancer | C61 | BCL2; TERT |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1; MET; DNMT1 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | DNMT1; DNMT1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; ADRA2C; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; DNMT1; DNMT1 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| NA: NA | Inflammatory diseases | NA | MAPK14 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| C00-D49: Neoplasms | Multiple myeloma | C90 | BCL2; TERT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2C; ADRA2A; FAAH; PTGS1; ACHE; PKM |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
| C00-D49: Neoplasms | Melanoma | C43 | TERT |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| C00-D49: Neoplasms | Leukemia | C90-C95 | BCL2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; PTGS1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; PPARG |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ADRA2C; ACHE |
| NA: NA | Rheumatold arthritis | NA | MAPK14; PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; ACHE; ACHE; ACHE; MAPT; APP; PPARG; PPARG |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | MAPK14; PTGS1; PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MAPK14; FAAH; PTGS1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MAPK14 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| C00-D49: Neoplasms | Breast cancer | C50 | BCL2; TERT |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | FAAH; ACHE |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MAPK14 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; NR1I2 |